Abstract
Background: Various clinical studies have provided estimates of life expectancy of patients with mild cognitive impairment (MCI) from outpatient clinics, but whether these apply to community-dwelling individuals at home or in primary care is uncertain. Methods: Within the population-based Rotterdam Study, we studied life expectancy with and without dementia in 648 community-dwelling persons with MCI and 6410 without MCI. Participants aged 60 years and older were assessed for MCI at baseline (2002–2014) and subsequently followed for the onset of dementia and death. We used multistate life tables to determine age-specific life expectancy with and without dementia by sex, educational attainment, and MCI subtype. Results: Total life expectancy for MCI ranged from 21.4 years (95% CI: 19.0–23.6) at age 60 to 2.6 years (1.6–3.6) at age 95. With advancing age, an increasing proportion of these years was lived with dementia (2.9 years [1.8–4.0] at age 60; 1.2 [0.2–2.2] at age 95). Women and higher educated individuals lived longer and lived more years with dementia. No differences in total life expectancy were observed by MCI subtype, although individuals with amnestic MCI lived a larger proportion of those years with dementia. Conclusions: Prognosis of MCI, in terms of life years lived with and without dementia, is more favorable in the general population than described in prior clinical observations, due likely to a substantial proportion of individuals with MCI in the clinic not seeking medical attention in an earlier stage.
| Original language | English |
|---|---|
| Pages (from-to) | 481-489 |
| Number of pages | 9 |
| Journal | Journal of the American Geriatrics Society |
| Volume | 70 |
| Issue number | 2 |
| Early online date | 18 Oct 2021 |
| DOIs | |
| Publication status | Published - Feb 2022 |
Bibliographical note
Funding Information:The contributions of the study participants, the staff from the Rotterdam Study, and the participating general practitioners and pharmacists are gratefully acknowledged. The Rotterdam Study is supported by the Erasmus MC University Medical Center and Erasmus University Rotterdam; The Netherlands Organization for Scientific Research (NWO); The Netherlands Organization for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); The Netherlands Genomics Initiative (NGI); the Ministry of Education, Culture and Science; the Ministry of Health, Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. This study was partly performed as part of the Netherlands Consortium of Dementia Cohorts (NCDC), which receives funding in the context of Deltaplan Dementie from ZonMW Memorabel (Project Number 73305095005) and Alzheimer Nederland.
Funding Information:
Alzheimer Nederland; ZonMW Memorabel, Grant/Award Number: 73305095005; Municipality of Rotterdam; European Commission (DG XII); Ministry of Health, Welfare and Sports; Ministry of Education, Culture and Science; The Netherlands Genomics Initiative (NGI); Research Institute for Diseases in the Elderly (RIDE); The Netherlands Organization for Health Research and Development (ZonMw); The Netherlands Organization for Scientific Research (NWO); Erasmus University Rotterdam; Erasmus MC University Medical Center Funding information
Publisher Copyright:
© 2021 The Authors. Journal of the American Geriatrics Society published by Wiley Periodicals LLC on behalf of The American Geriatrics Society.
